Indicators
Indicators
Value
Direction
MACD(12,26,9)
--
--
RSI(14)
--
--
STOCH(KDJ)(9,3,3)
--
--
ATR(14)
--
--
CCI(14)
--
--
Williams %R
--
--
TRIX(12,20)
--
--
StochRSI(14)
--
--
Eli Lilly and Co
LLYView Detailed Chart
884.490USD
+24.759+2.88%
Close 04/25, 16:00（ET）Quotes delayed by 15 min
838.09BMarket Cap
79.14P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+2.88%
5 Days
+5.30%
1 Month
+6.98%
6 Months
-0.92%
Year to Date
+14.57%
1 Year
+20.58%
View Detailed Chart
Agency Rating
Analyst Rating
Based on
29
analysts
BUY
Current Rating
1016.050
Target Price
14.87%
Rising Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
8
Average
Company name
Ratings
Analysts
Eli Lilly and Co
LLY
29
Biogen Inc
BIIB
37
Vertex Pharmaceuticals Inc
VRTX
34
Alnylam Pharmaceuticals Inc
ALNY
33
Amgen Inc
AMGN
33
Gilead Sciences Inc
GILD
30
1
2
3
...
32
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Neutral
Moving Average
Indicators
Value
Direction
MA5
--
--
MA10
--
--
MA20
--
--
MA50
--
--
MA100
--
--
MA200
--
--
News
Lilly sues four compounders over copies of weight-loss drugs
April 23 (Reuters) - Eli Lilly LLY.N said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S. judge last month blocked pharmacies from making copies of its weight-loss and diabetes medicines.odu...
ReutersWed, Apr 23
.jpg)
Lilly weight-loss pill works as well as Ozempic, shares surge
April 17 (Reuters) - Eli Lilly's LLY.N experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of diabetes patients, and the company said it expects to seek regulatory approvals by the end of the year.
ReutersFri, Apr 18
US STOCKS-S&P 500 ends up as Eli Lilly jumps and UnitedHealth plummets
April 17 (Reuters) - The S&P 500 ended higher on Thursday, lifted by Eli Lilly and Apple, as investors weighed progress in U.S. trade negotiations with Japan against concerns about the interest rate outlook.Traders leaned toward optimism following U.S. President Donald Trump's comments about "big..
ReutersFri, Apr 18
Facing a Trumpcession: What Options Remain for Stock Investors?
TradingKey - While Wednesday's CPI data came in below expectations, alleviating some market fears, intra-day trading remained volatile, indicating that investors are still seeking more data for further assessment.
TradingKeyWed, Mar 12
BRIEF-Organovo’S FXR Program, Including FXR314, To Be Acquired By Eli Lilly And Company
Feb 25 (Reuters) - Eli Lilly and Co LLY.N:ORGANOVO’S FXR PROGRAM, INCLUDING FXR314, TO BE ACQUIRED BY ELI LILLY AND COMPANY ORGANOVO HOLDINGS INC - TO RECEIVE UPFRONT PAYMENT AND MILESTONES FOR FXR314 ORGANOVO HOLDINGS INC - LILLY ACQUIRES ALL COMMERCIAL AND IP RIGHTS TO FXR PROGRAM
ReutersTue, Feb 25
Company
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; and Zepbound. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of α4β7 integrin for inflammatory bowel disease (IBD). It also owns a lead therapeutic molecule FXR314.
Company codeLLY
CompanyEli Lilly and Co
CEOMr. David A. (Dave) Ricks
Websitehttps://www.lilly.com/
Related Instruments
Johnson & Johnson
-0.26%
AbbVie Inc
+3.16%
Novartis AG
+0.86%
AstraZeneca PLC
+0.03%
Merck & Co Inc
+3.64%
Novo Nordisk A/S
-0.89%
Amgen Inc
+0.36%
Sanofi SA
-2.28%
Pfizer Inc
+0.66%
Gilead Sciences Inc
-2.81%
Vertex Pharmaceuticals Inc
+0.28%
Bristol-Myers Squibb Co
-1.67%
Haleon PLC
-1.21%
Mckesson Corp
+0.90%
GSK plc
-0.19%
Zoetis Inc
+0.79%
Cardinal Health Inc
+1.24%
Alnylam Pharmaceuticals Inc
+3.69%
Takeda Pharmaceutical Co Ltd
-0.56%
Biogen Inc
-0.56%
